Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00436-022-07478-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High dose aflibercept treatment in naive neovascular age-related macular degeneration.
Int Ophthalmol
January 2025
Beyoglu Eye Training and Research Hospital, University of Health Sciences, Bereketzade Camii Sk. No:2 Beyoğlu, 34421, Istanbul, Turkey.
Background: To evaluate the efficacy and safety of intravitreal injections of 4 mg (high dose) of aflibercept in treatment-naive patients with neovascular AMD(nAMD) with treat and extend(TREX) dosing regimens, and to determine the frequency of injections.
Methods: In this interventional, retrospective study a total of 15 eyes of 14 patients (eight female and 9 male) with nAMD were included. All patients were examined and OCT imaging was performed at the time of initial presentation, on the day of each injection and at subsequent follow-up visits.
Cardiovascular Complications Following Acute Methadone Poisoning in Patients with and Without a History of Long-term Methadone Use.
J Res Pharm Pract
December 2024
Department of Clinical Toxicology, Isfahan University of Medical Sciences, Isfahan, Iran.
Objective: Given the prevalence of methadone poisoning, this study was conducted to compare the cardiovascular complications following acute methadone poisoning in patients with and without a history of long-term methadone use.
Methods: In this retrospective study, information related to patients with acute methadone poisoning hospitalized at Al-Zahra and Khorshid hospitals in Isfahan-Iran was collected from hospital archives and analyzed. Patients were divided into two groups with and without a history of long-term methadone use.
Automatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid.
Ther Adv Drug Saf
January 2025
Department of Epidemiology, Biostatistics and Health Data, Centre Antoine Lacassagne, Nice, France.
Background: Reporting serious adverse events (SAEs) is crucial to reduce or avoid toxicities that can lead to major consequences for patient's health due to treatments tested in clinical trials. Its exhaustiveness is often inadequate, and we observe discrepancies between data published by pharmacovigilance organizations and clinical databases.
Objectives: While the process of reconciliation aims at reducing these differences, it remains a very time-consuming and imprecise task.
Optimizing Surgical Correction of Symblepharon Secondary to Lower Eyelid Burn Scar.
Cureus
December 2024
Plastic and Reconstructive Surgery, Hospital de Santa Maria, Unidade Local de Saúde de Santa Maria (ULSSM), Lisbon, PRT.
The healing of lower eyelid injuries can lead to anatomical distortion and compromise the function of multiple periocular structures. To restore eyelid function and aesthetics, it is crucial to establish an accurate diagnosis and provide appropriate treatment to the affected structures. The presented case describes the diagnosis and surgical treatment of a lower eyelid symblepharon, which can be easily misdiagnosed as other scarring sequelae.
View Article and Find Full Text PDFSuccessful Laparoscopic Sleeve Gastrectomy in a Patient With Rare Congenital Factor VII Deficiency: A Case Report and Management Strategy.
Cureus
December 2024
Department of Surgery, King Abdulaziz Specialist Hospital, Taif, SAU.
Congenital factor VII (FVII) deficiency is a rare coagulation disorder that increases the risk of bleeding complications during surgery. Although laparoscopic sleeve gastrectomy (LSG) is the most common metabolic bariatric surgery (MBS), it is rarely performed in patients with congenital coagulation disorders such as FVII deficiency, due to the high risk of intraoperative and postoperative bleeding. We report the case of a 57-year-old female with class II obesity (BMI 37.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!